BioLineRx
BioLineRx (), or BioLine, is a publicly traded drug development company that seeks to discover compounds for disease treatment and develop them into commercializable drugs. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Corporate history. The firm was established in 2003 as a joint venture of Teva, Hadasit Bio-Holdings, the Jerusalem Development Authority, Yehuda Zisapel, and other investors. It executed an initial public offering on the Tel Aviv Stock Exchange in February 2007, raising 211 million NIS ($50 million) – the TASE's largest biotech IPO until that  time. In July 2011 BioLine's ADRs began trading on the NASDAQ Capital Market. In January 2012, the firm announced a deal with Genoscience, a French pharmaceutical company to jointly develop and market the BL-8020 compound, as a treatment for Hepatitis C. At the end of 2014, Novartis acquired a 12.8% stake in the company as a strategic move to gain access to Israeli-sourced drug candidates. Management. Morris Laster, (M.D.) an alumnus of. Downstate Medical Center, was CEO of BioLineRx until 2009. He was replaced by Kinneret Savitsky, alumnus of Tel Aviv University early in 2010. Savitsky was replaced  as CEO by BioLine COO Philip Serlin on October 10, 2016. Operations. BioLineRx is a drug development company When promising compounds are discovered, the firm leads them through preclinical trials and engages other companies to further develop them into commercializable drugs. The company entered into its first major commercialization agreement in 2009 when it partnered with Ikaria Holdings Inc. to develop its BL-1040 compound. In 2010, BioLine entered into a commercialization agreement with Cypress Bioscience Inc. for development of its BL-1020 compound. The agreement with Cypress was canceled in 2011 when the company was taken over by Ramius LLC. Pipeline . Below is a partial list of drug compounds in various stages of development by BioLineRx. Unless indicated otherwise, they have not obtained regulatory approval in relation to the diseases cited.